Table 3 Treatment emergent adverse events in newly diagnosed and relapsed/refractory patients with IDH2 mutant acute myeloid leukemia.

From: Efficacy and safety of enasidenib and azacitidine combination in patients with IDH2 mutated acute myeloid leukemia and not eligible for intensive chemotherapy

TEAE

Newly diagnosed n = 7

Relapsed/refractory n = 19

IDH-DS

1 (14)

1 (5)

Febrile neutropenia ≥Gr 3

1 (14)

5 (26)

ALT ≥ Gr 3

0

1(5)

AST ≥ Gr 3

0

1(5)

Total bilirubin ≥Gr 3

2 (29)

7(37)

GI (any grade)

Nausea

0

1 (5)

Vomiting

0

2(11)

Diarrhea

0

4 (21)

  1. TEAE- Treatment emergent adverse event, IDH-DS- IDH inhibitor induced differentiation syndrome, AST- Aspartate aminotransferase, ALT- Alanine aminotransferase, GI- Gastrointestinal
  2. All results expressed as No. (%) or median [Minimum - maximum], unless specified.
Back to article page